Advertisement

Journal of Molecular Neuroscience

, Volume 68, Issue 1, pp 153–161 | Cite as

Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod

  • Mohammad Mahdi Eftekharian
  • Alireza Komaki
  • Mehrdokht Mazdeh
  • Shahram Arsang-Jang
  • Mohammad TaheriEmail author
  • Soudeh Ghafouri-FardEmail author
Article

Abstract

Multiple sclerosis (MS) as a chronic autoimmune disease of the central nervous system (CNS) has been associated with dysregulation of several genes including miRNAs. In the present study, we assessed transcript levels of seven miRNAs (miR-96-5p, miR-211-5p, miR-15a, miR-34a-5p, miR-204-5p, miR-501-5p, and miR-524-5p) in the peripheral blood of MS patients compared with healthy subjects in association with response to fingolimod treatment. Expression levels of miR-211-5p and miR-34a-5p were significantly decreased in MS patients compared with healthy subjects (P values of 0.002 and 0.47). While subgroup analysis showed downregulation of miR-211-5p in both fingolimod responders and non-responders, miR-34a-5p expression was only decreased in responders. Moreover, miR-204-5p was downregulated in non-responder male patients compared with male controls. The current study underscores the role of miRNAs in determination of response to fingolimod in MS patients.

Keywords

Multiple sclerosis Fingolimod miRNA 

Notes

Author Contributions

SGF wrote the manuscript. MT supervised the study. SAJ analyzed the data. MM was the clinical consultant. AK and RS conducted the bioinformatics analyses. MME performed the laboratory assessment.

Funding Information

The current study was supported by grant number 9512177928 from Hamadan University of Medical Sciences.

Compliance with Ethical Standards

The study protocol was approved by the local ethics committee of Hamadan University of Medical Sciences (IR.UMSHA.REC.1395.506). Written informed consent forms were obtained from all study participants. We confirmed that all methods were performed in accordance with the relevant guidelines and regulations.

Competing Interests

The authors declare that they have no conflict of interest.

References

  1. Bekenstein U, Mishra N, Milikovsky DZ, Hanin G, Zelig D, Sheintuch L, Berson A, Greenberg DS, Friedman A, Soreq H (2017) Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity. Proc Natl Acad Sci U S A 114:E4996–E5005CrossRefGoogle Scholar
  2. Cahill EF, Tobin LM, Carty F, Mahon BP, English K (2015) Jagged-1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther 6:19CrossRefGoogle Scholar
  3. Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J (2018) Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatr 89(8):844–850CrossRefGoogle Scholar
  4. Chen L, Zhang W, Yan W, Han L, Zhang K, Shi Z, Zhang J, Wang Y, Li Y, Yu S (2012) The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis 33:2276–2282CrossRefGoogle Scholar
  5. Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ, Broadley S, Scott RJ, Booth DR, Lechner-Scott J (2010) MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS One 5:e12132CrossRefGoogle Scholar
  6. Dastmalchi R, Ghafouri-Fard S, Omrani MD, Mazdeh M, Sayad A, Taheri M (2018) Dysregulation of long non-coding RNA profile in peripheral blood of multiple sclerosis patients. Mult Scler Relat Disord 25:219–226CrossRefGoogle Scholar
  7. Ebrahimkhani S, Vafaee F, Young PE, Hur SSJ, Hawke S, Devenney E, Beadnall H, Barnett MH, Suter CM, Buckland ME (2017) Exosomal microRNA signatures in multiple sclerosis reflect disease status. Sci Rep 7:14293CrossRefGoogle Scholar
  8. Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, Klinkenberg K, Kotterba S, Mohring M, Sindern E (2004) Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. Acta Neurol Scand 109:385–389CrossRefGoogle Scholar
  9. Fenoglio C, de Riz M, Pietroboni AM, Calvi A, Serpente M, Cioffi SM, Arcaro M, Oldoni E, Scarpini E, Galimberti D (2016) Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. J Neuroimmunol 299:81–83CrossRefGoogle Scholar
  10. Friess J, Hecker M, Roch L, Koczan D, Fitzner B, Angerer IC, Schroder I, Flechtner K, Thiesen HJ, Winkelmann A, Zettl UK (2017) Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis. Sci Rep 7Google Scholar
  11. Fuchs Wightman F, Giono LE, Fededa JP, De La Mata M (2018) Target RNAs strike back on microRNAs. Front Genet 9:435CrossRefGoogle Scholar
  12. Ghadiri N, Emamnia N, Ganjalikhani-Hakemi M, Ghaedi K, Etemadifar M, Salehi M, Shirzad H, Nasr-Esfahani MH (2018) Analysis of the expression of mir-34a, mir-199a, mir-30c and mir-19a in peripheral blood CD4+ T lymphocytes of relapsing-remitting multiple sclerosis patients. Gene 659:109–117CrossRefGoogle Scholar
  13. Hecker M, Thamilarasan M, Koczan D, Schroder I, Flechtner K, Freiesleben S, Fullen G, Thiesen HJ, Zettl UK (2013) MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients. Int J Mol Sci 14:16087–16110CrossRefGoogle Scholar
  14. Huan T, Chen G, Liu C, Bhattacharya A, Rong J, Chen BH, Seshadri S, Tanriverdi K, Freedman JE, Larson MG (2018) Age-associated micro RNA expression in human peripheral blood is associated with all-cause mortality and age-related traits. Aging Cell 17:e12687CrossRefGoogle Scholar
  15. Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, Lassmann H, Wekerle H, Hohlfeld R, Meinl E (2009) MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132:3342–3352CrossRefGoogle Scholar
  16. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, Lenhof HP, Ruprecht K, Meese E (2009) Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 4:e7440CrossRefGoogle Scholar
  17. Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L (2010) Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol 40:888–898CrossRefGoogle Scholar
  18. Luo DL, Fu J (2018) Identifying characteristic miRNAs—genes and risk pathways of multiple sclerosis based on bioinformatics analysis. Oncotarget 9:5287–5300Google Scholar
  19. Otaegui D, Baranzini SE, Armananzas R, Calvo B, Munoz-Culla M, Khankhanian P, Inza I, Lozano JA, Castillo-Trivino T, Asensio A, Olaskoaga J, Lopez De Munain A (2009) Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 4:e6309CrossRefGoogle Scholar
  20. Pang RT, Leung CO, Ye T-M, Liu W, Chiu PC, Lam KK, Lee K-F, Yeung WS (2010) MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31:1037–1044CrossRefGoogle Scholar
  21. Rahimi M, Aghabozorg Afjeh SS, Omrani MD, Arsang-Jang S, Ganji M, Noroozi R, Taheri M, Ghafouri-Fard S (2018) Soluble receptor for advanced glycation end products (sRAGE) is up-regulated in multiple sclerosis patients treated with interferon beta-1a. Cell Physiol Biochem 46:561–567CrossRefGoogle Scholar
  22. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R, Comabella M, Montalban X (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59:344–352CrossRefGoogle Scholar
  23. Rosas-Ballina M, Tracey KJ (2009) Cholinergic control of inflammation. J Intern Med 265:663–679CrossRefGoogle Scholar
  24. Saenz-Cuesta M, Alberro A, Munoz-Culla M, Osorio-Querejeta I, Fernandez-Mercado M, Lopetegui I, Tainta M, Prada A, Castillo-Trivino T, Falcon-Perez JM, Olascoaga J, Otaegui D (2018) The first dose of fingolimod affects circulating extracellular vesicles in multiple sclerosis patients. Int J Mol Sci 19Google Scholar
  25. Sayad A, Ghafouri-Fard S, Omrani MD, Noroozi R, Taheri M (2017) Myxovirus resistance protein A (MxA) polymorphism is associated with IFNbeta response in Iranian multiple sclerosis patients. Neurol Sci 38:1093–1099CrossRefGoogle Scholar
  26. Sievers C, Meira M, Hoffmann F, Fontoura P, Kappos L, Lindberg RL (2012) Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin Immunol 144:70–79CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Neurophysiology Research CenterHamadan University of Medical SciencesHamadanIran
  2. 2.Clinical Research Development Center (CRDU)Qom University of Medical SciencesQomIran
  3. 3.Urogenital Stem Cell Research CenterShahid Beheshti University of Medical SciencesTehranIran
  4. 4.Department of Medical GeneticsShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations